. 2019 Apr 2;36(7):1756–1769. doi: 10.1007/s12325-019-00940-7

Table 1.

Timing of visits and schedule of assessments

Assessment	Visit 1 (baseline) Pre-switch/study start	Visit 2 (control visit) Week 2 (+ 1 week)	Visit 3 (end of study) Week 12 (+ 2 weeks)^a
Informed consent	X
Inclusion/exclusion criteria	X
Demography	X
Concomitant medication	X
Smoking status	X
Patient questionnaire	X^b	X^c	X^c
Patient assessment of device handling and inhalation technique	X^b	X^c	X^c
Physician/nurse assessment of teaching and inhaler use	X^c	X^c	X^c
Asthma control test	X^b		X^c
Mini-AQLQ	X^b		X^c
Spirometry	X^b		X^c
Adverse events		X^c	X^c

AQLQ Asthma Quality of Life Questionnaire, B/F budesonide and formoterol fumarate

^aOr early withdrawal from study

^bAssessment of B/F Turbuhaler^®

^cAssessment of B/F Easyhaler^®